-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Approves Genentech's Wilserdly Combination for Advanced Breast Cancer

PUBT·11/16/2026 22:23:58
Listen to the news
FDA Approves Genentech's Wilserdly Combination for Advanced Breast Cancer
  • FDA approves Genentech’s Wilserdly with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
  • The combination reduced the risk of disease progression or death by 62% versus standard endocrine therapy with everolimus in ESR1-mutated patients.
  • A separate FDA review of Wilserdly for adjuvant breast cancer treatment has a decision deadline of November 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.